🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "significant breakthrough" in the battle against increasingly resistant strains of the pathogen, according to health experts.

A Global Health Concern

Cases of gonorrhoea are on the rise worldwide, with estimates suggesting over 82 million new cases each year. Notably increased rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the reality of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options presently on offer.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance found that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists anticipate that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GSK, gained clearance in the same week. This drug, which is also used to treat urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The charitable organization GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This authorization represents a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Results and Global Access

According to results released by a major medical journal, zoliflodacin cured more than 90% of cases of the STI. This places it at an equal footing with the existing first-line therapy, which involves two antibiotics. The study enrolled over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the rights to license and sell the drug in numerous low-income and middle-income countries.

Doctors directly involved have voiced optimism. Having a single-dose, oral treatment like this is described as a "game-changer" for managing the epidemic. This is viewed as crucial to lessen the impact of the disease for people and to stop the proliferation of extremely resistant gonorrhoea around the world.